Akzo Nobel India Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 8, 2025, 5:39 am

Competitors of Akzo Nobel India Ltd

All Competitor Stocks of Akzo Nobel India Ltd

Quarterly Result

Last Updated: August 20, 2025, 2:05 pm

Below is a detailed analysis of the quarterly data for Akzo Nobel India Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 995.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,022.00 Cr. (Mar 2025) to 995.00 Cr., marking a decrease of 27.00 Cr..
• For Expenses, as of Jun 2025, the value is 861.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 863.00 Cr. (Mar 2025) to 861.00 Cr., marking a decrease of 2.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 134.00 Cr.. The value appears to be declining and may need further review. It has decreased from 159.00 Cr. (Mar 2025) to 134.00 Cr., marking a decrease of 25.00 Cr..
• For OPM %, as of Jun 2025, the value is 14.00%. The value appears to be declining and may need further review. It has decreased from 16.00% (Mar 2025) to 14.00%, marking a decrease of 2.00%.
• For Other Income, as of Jun 2025, the value is 9.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Mar 2025) to 9.00 Cr., marking an increase of 6.00 Cr..
• For Interest, as of Jun 2025, the value is 3.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.00 Cr. (Mar 2025) to 3.00 Cr., marking an increase of 1.00 Cr..
• For Depreciation, as of Jun 2025, the value is 18.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 22.00 Cr. (Mar 2025) to 18.00 Cr., marking a decrease of 4.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 122.00 Cr.. The value appears to be declining and may need further review. It has decreased from 137.00 Cr. (Mar 2025) to 122.00 Cr., marking a decrease of 15.00 Cr..
• For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 22.00% (Mar 2025) to 26.00%, marking an increase of 4.00%.
• For Net Profit, as of Jun 2025, the value is 91.00 Cr.. The value appears to be declining and may need further review. It has decreased from 108.00 Cr. (Mar 2025) to 91.00 Cr., marking a decrease of 17.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 19.98. The value appears to be declining and may need further review. It has decreased from 23.61 (Mar 2025) to 19.98, marking a decrease of 3.63.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: August 22, 2025, 5:20 pm

Growth

Last Updated: September 4, 2025, 10:40 pm

Balance Sheet

Last Updated: June 16, 2025, 12:31 pm

Below is a detailed analysis of the balance sheet data for Akzo Nobel India Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 46.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 46.00 Cr..
• For Reserves, as of Mar 2025, the value is 1,283.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,284.00 Cr. (Mar 2024) to 1,283.00 Cr., marking a decrease of 1.00 Cr..
• For Borrowings, as of Mar 2025, the value is 62.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 60.00 Cr. (Mar 2024) to 62.00 Cr., marking an increase of 2.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 1,511.00 Cr.. The value appears to be improving (decreasing). It has decreased from 1,513.00 Cr. (Mar 2024) to 1,511.00 Cr., marking a decrease of 2.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 2,902.00 Cr.. The value appears to be improving (decreasing). It has decreased from 2,903.00 Cr. (Mar 2024) to 2,902.00 Cr., marking a decrease of 1.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 481.00 Cr.. The value appears to be declining and may need further review. It has decreased from 526.00 Cr. (Mar 2024) to 481.00 Cr., marking a decrease of 45.00 Cr..
• For CWIP, as of Mar 2025, the value is 67.00 Cr.. The value appears to be declining and may need further review. It has decreased from 119.00 Cr. (Mar 2024) to 67.00 Cr., marking a decrease of 52.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 2,354.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,258.00 Cr. (Mar 2024) to 2,354.00 Cr., marking an increase of 96.00 Cr..
• For Total Assets, as of Mar 2025, the value is 2,902.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,903.00 Cr. (Mar 2024) to 2,902.00 Cr., marking a decrease of 1.00 Cr..

Notably, the Reserves (1,283.00 Cr.) exceed the Borrowings (62.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Akzo Nobel India Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 94.31. This value is within the healthy range. It has increased from 93.68 (Mar 24) to 94.31, marking an increase of 0.63.
• For Diluted EPS (Rs.), as of Mar 25, the value is 94.31. This value is within the healthy range. It has increased from 93.68 (Mar 24) to 94.31, marking an increase of 0.63.
• For Cash EPS (Rs.), as of Mar 25, the value is 114.04. This value is within the healthy range. It has increased from 111.85 (Mar 24) to 114.04, marking an increase of 2.19.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 292.09. It has increased from 292.02 (Mar 24) to 292.09, marking an increase of 0.07.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 292.35. It has increased from 292.29 (Mar 24) to 292.35, marking an increase of 0.06.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 899.16. It has increased from 870.68 (Mar 24) to 899.16, marking an increase of 28.48.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 147.05. This value is within the healthy range. It has increased from 146.77 (Mar 24) to 147.05, marking an increase of 0.28.
• For PBIT / Share (Rs.), as of Mar 25, the value is 127.41. This value is within the healthy range. It has decreased from 128.68 (Mar 24) to 127.41, marking a decrease of 1.27.
• For PBT / Share (Rs.), as of Mar 25, the value is 125.25. This value is within the healthy range. It has decreased from 125.93 (Mar 24) to 125.25, marking a decrease of 0.68.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 94.39. This value is within the healthy range. It has increased from 93.76 (Mar 24) to 94.39, marking an increase of 0.63.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 94.39. This value is within the healthy range. It has increased from 93.76 (Mar 24) to 94.39, marking an increase of 0.63.
• For PBDIT Margin (%), as of Mar 25, the value is 16.35. This value is within the healthy range. It has decreased from 16.85 (Mar 24) to 16.35, marking a decrease of 0.50.
• For PBIT Margin (%), as of Mar 25, the value is 14.16. This value is within the healthy range. It has decreased from 14.77 (Mar 24) to 14.16, marking a decrease of 0.61.
• For PBT Margin (%), as of Mar 25, the value is 13.92. This value is within the healthy range. It has decreased from 14.46 (Mar 24) to 13.92, marking a decrease of 0.54.
• For Net Profit Margin (%), as of Mar 25, the value is 10.49. This value exceeds the healthy maximum of 10. It has decreased from 10.76 (Mar 24) to 10.49, marking a decrease of 0.27.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 10.49. This value is within the healthy range. It has decreased from 10.76 (Mar 24) to 10.49, marking a decrease of 0.27.
• For Return on Networth / Equity (%), as of Mar 25, the value is 32.31. This value is within the healthy range. It has increased from 32.10 (Mar 24) to 32.31, marking an increase of 0.21.
• For Return on Capital Employeed (%), as of Mar 25, the value is 39.88. This value is within the healthy range. It has increased from 39.55 (Mar 24) to 39.88, marking an increase of 0.33.
• For Return On Assets (%), as of Mar 25, the value is 14.79. This value is within the healthy range. It has increased from 14.69 (Mar 24) to 14.79, marking an increase of 0.10.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.41. It has increased from 1.40 (Mar 24) to 1.41, marking an increase of 0.01.
• For Current Ratio (X), as of Mar 25, the value is 1.38. This value is below the healthy minimum of 1.5. It has increased from 1.35 (Mar 24) to 1.38, marking an increase of 0.03.
• For Quick Ratio (X), as of Mar 25, the value is 0.96. This value is below the healthy minimum of 1. It has increased from 0.92 (Mar 24) to 0.96, marking an increase of 0.04.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.56. This value is below the healthy minimum of 4. It has increased from 3.32 (Mar 24) to 3.56, marking an increase of 0.24.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 100.72. This value exceeds the healthy maximum of 50. It has increased from 96.08 (Mar 24) to 100.72, marking an increase of 4.64.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 83.36. This value exceeds the healthy maximum of 50. It has increased from 80.54 (Mar 24) to 83.36, marking an increase of 2.82.
• For Earning Retention Ratio (%), as of Mar 25, the value is -0.72. This value is below the healthy minimum of 40. It has decreased from 3.92 (Mar 24) to -0.72, marking a decrease of 4.64.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 16.64. This value is below the healthy minimum of 40. It has decreased from 19.46 (Mar 24) to 16.64, marking a decrease of 2.82.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 68.28. This value is within the healthy range. It has increased from 53.42 (Mar 24) to 68.28, marking an increase of 14.86.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 44.83. This value is within the healthy range. It has increased from 35.13 (Mar 24) to 44.83, marking an increase of 9.70.
• For Enterprise Value (Cr.), as of Mar 25, the value is 16,078.36. It has increased from 10,323.76 (Mar 24) to 16,078.36, marking an increase of 5,754.60.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.93. This value exceeds the healthy maximum of 3. It has increased from 2.61 (Mar 24) to 3.93, marking an increase of 1.32.
• For EV / EBITDA (X), as of Mar 25, the value is 24.03. This value exceeds the healthy maximum of 15. It has increased from 15.46 (Mar 24) to 24.03, marking an increase of 8.57.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.00. This value exceeds the healthy maximum of 3. It has increased from 2.74 (Mar 24) to 4.00, marking an increase of 1.26.
• For Retention Ratios (%), as of Mar 25, the value is -0.72. This value is below the healthy minimum of 30. It has decreased from 3.91 (Mar 24) to -0.72, marking a decrease of 4.63.
• For Price / BV (X), as of Mar 25, the value is 12.32. This value exceeds the healthy maximum of 3. It has increased from 8.16 (Mar 24) to 12.32, marking an increase of 4.16.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.00. This value exceeds the healthy maximum of 3. It has increased from 2.74 (Mar 24) to 4.00, marking an increase of 1.26.
• For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness